title: [Inhibition of human glioma cell growth by a soluble recombinant human CD40 ligand].
abstract: OBJECTIVE
  CD40 presents on B cells, monocytes, dendritic cells, and endothelial cells, as well as a variety of neoplastic cell types, including carcinomas. CD40 stimulated by its antibody or CD40 ligand previously had been demonstrated to induce activation-induced cell death in ovarian carcinoma cell lines, colon carcinoma cell lines, breast carcinoma cell lines, and lung carcinoma cell lines and to inhibit their growth in vivo. This study was designed to assess the effects of a recombinant soluble human CD40 ligand (srhCD40L) on human glioma cell lines.
  
  
  METHODS
  The specimens of human glioma were examined for CD40 expression by immunohistochemistry. The human glioma cell lines were examined for CD40 expression by flow cytometry. The cell lines were incubated with srhCD40L for 24h and 72h, then the markers of proliferation and apoptosis of these cells were determined, respectively.
  
  
  RESULTS
  CD40 expression could be detected in 7/23 human glioma specimens and 1/3 cell line. The srhCD40L inhibited the proliferation of CD40+ human glioma cell line. The viability of these cells was decreased from 98% to 87%. The apoptosis and death of these cells were increased by 17.4%.
  
  
  CONCLUSIONS
  CD40 stimulated by its ligand directly inhibits human glioma cell growth in vitro. These results suggest that srhCD40L may be of clinic use to inhibit glioma growth.
authors.affiliation: Department of Neurosurgery, the Affiliated Hospital, Nantong Medical College, Nantong 226001, P. R. China. yilugao@hotmail.com
authors.forename: Yi-lu
authors.initials: YL
authors.lastname: Gao
authors.forename: Hong-zhen
authors.initials: HZ
authors.lastname: Shi
authors.forename: Mei
authors.initials: M
authors.lastname: Liu
authors.forename: Xiao-song
authors.initials: XS
authors.lastname: Gu
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D019013:CD40 Antigens / Q000096:biosynthesis / Q000187:drug effects; D023201:CD40 Ligand / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005910:Glioma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D011994:Recombinant Proteins / Q000494:pharmacology; D012995:Solubility; D014407:Tumor Cells, Cultured
chemical_list: D019013:CD40 Antigens; D011994:Recombinant Proteins; D023201:CD40 Ligand